Diabetes mellitus is an independent risk factor for cardiovascular disease


Cite item

Full Text

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases, the incidence of which tends to grow steadily. The great social importance of diabetes mellitus is determined by disability and deaths from late vascular events. So the risk for cardiovascular disease (CVD) and the cardiovascular safety of glucose-lowering therapy for T2DM are a multidisciplinary and multi-faceted problem. Its solution requires a comprehensive approach to controlling the risk factors of CVD and assessing hypoglycemic therapy in the context of cardiovascular safety. The paper shows the bases of CVD pathogenesis and contains the results of numerous international clinical trials evaluating the efficiency and safety of current glucose-lowering therapy (metformin and cardioprotective drugs, the action of which is based on their incretin effect).

Full Text

Сахарный диабет - независимый фактор риска развития сердечно-сосудистых заболеваний. - Аннотация. Сахарный диабет 2-го типа (СД2) - одно из наиболее распространенных хронических заболеваний, частота развития которого имеет тенденцию к неуклонному росту. Большая социальная значимость СД обусловлена инвалидизацией и смертностью от поздних сосудистых осложнений. Поэтому проблема риска развития сердечно-сосудистых заболеваний (ССЗ) и сердечно-сосудистой безопасности проводимой сахароснижающей терапии при СД2 является мультидисциплинарной и разноплановой. Для ее решения требуется комплексный поход как в плане контроля существующих у пациента факторов риска развития ССЗ, так и оценки гипогликемической терапии с позиций сердечно-сосудистой безопасности. В статье раскрыты основы патогенеза ССЗ и содержатся результаты многочисленных международных клинических исследований по оценке эффективности и безопасности современной сахароснижающей терапии (метформин и обладающие кардиопротективными свойствами препараты, действие которых основано на инкретиновом эффекте).
×

References

  1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 1: 4-14.
  2. Государственный регистр больных сахарным диабетом, 2009.
  3. Niskanen L., Turpeinrn A., Penttila I., Uusitupa M.I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998; 21: 11: 1861-1869.
  4. Malmberg K., Rydén L., Wedel H. et al. for the DIGAMI 2 Investigators Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.
  5. Stratton J.M., Adler A.I., Neil A.W. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. Br Mtd J 2000 321; 405-412.
  6. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
  7. Yusuf S., Hawken S., Ôunpuu S. et al. for the INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 9438: 937-952.
  8. Cefalu W.T. Glycemic targets and cardiovascular disease. N Engl J Med 2008; 358: 2633-2635. doi: 10.1056/NEJMe0803831.
  9. Kelly T., Bazzano L., Fonseca V. et al. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 1-13.
  10. Ray K.K., Seshasai S.R., Wijesuriya S. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 9677: 1765-1772. doi: 10.1016/S0140-6736(09)60697-8.
  11. American Diabetes Association; National Hert, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Digestive and Kidney Disease; American Heart Association. Diabetes Mellitus: a major risk factor for cardiovascular disease. Circulation 1999; 100: 1132-1133.
  12. Wu M.S., Johnston P., Sheu W.H.H. et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8.
  13. Despres J.P. Potential contribution of metformin to the management of cardio- vascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diab Metabol 2003; 29: 6553-6561.
  14. Charles A., Vague P., Morange P. et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects. The BIGPROL Study. Diabetes Care 1998; 11: 1967-1972.
  15. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 9131: 837-853.
  16. Chan N. Improved endothelial function with metformin in type 2 diabetes mellitus. JAM Coll Cardial 2001; 38: 2131-2132.
  17. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343.
  18. Nauck M.A. Unraveling the science of incretin biology. Am J Med 2009; 122: S3-S10.
  19. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
  20. Дедов И.И., М.В. Шестакова. Инкретины: новая веха в лечении сахарного диабета 2 типа. М 2010: 34-35.
  21. Brixner D.I., McAdam-Marx C., Ye X. et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11: 12: 1122-1130.
  22. Apovian C.M., Bergenstal R.M., Cuddihy R.M. et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123: 5: 468.e9-17.
  23. Sullivan S.D., Alfonso-Cristancho R., Conner C. et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide of rosiglitazone. Cardiovasc Diabetol 2009; 26: 8: 12.
  24. Courreges J.P., Vilsboll Т., Zdravkovic M. et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetes Med 2008; 25: 9: 1129-1131.
  25. Bunck М.С., Diamant M., Eliasson В. et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33: 8: 1734-1737.
  26. Read P.A., Khan F.Z., Heck P.M. et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3: 2: 195-201.
  27. DCCT/EDIC Epidemiology of Diabetes Interventions and Complications Research randomized Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 2003; 348: 2294-2303.
  28. Tzoulaki I., Molokhia M., Curcin V. et al. Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: study using UK general practice research database. Br Mrd J 2009; 339: b4731.
  29. Evans J.M., Ogston S.A., Emslie-Smith A. et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas metformin. Diabetologia 2006; 49: 930-936.
  30. Johnson J.A., Majundar S.R., Simpson S.H. et al. Decreased mortality associated with the use of metformin compared with sulfonylurea in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
  31. Wolf R., Frederich R., Fiedorek F. et al. Evaluation of CV risk in saxagliptin clinical trials [abstract no.8-LB plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association. New Orleans 2009.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies